Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial

Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment

(2013) R. M. Connolly et al.   CLINICAL CANCER RESEARCH

LC–MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma

(2013) Brian F. Kiesel et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study

(2012) Don S. Dizon et al.   GYNECOLOGIC ONCOLOGY

Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

(2012) Don S. Dizon et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group

(2012) Winnie Yeo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

(2011) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

(2010) U Lassen et al.   BRITISH JOURNAL OF CANCER

Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway

(2008) Kun Wang et al.   BIOCHEMICAL PHARMACOLOGY

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH